Dexcom [DXCM] vs Stryker [SYK] Detailed Stock Comparison
Dexcom
NASDAQ
Loading...
Stryker
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Dexcom wins in 2 metrics, Stryker wins in 17 metrics, with 0 ties. Stryker appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Dexcom | Stryker | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 56.46 | 50.16 | Stryker |
| Price-to-Book Ratio | 12.22 | 6.81 | Stryker |
| Debt-to-Equity Ratio | 100.24 | 80.83 | Stryker |
| PEG Ratio | 39.49 | 7.26 | Stryker |
| EV/EBITDA | 33.67 | 24.84 | Stryker |
| Profit Margin (TTM) | 13.29% | 12.25% | Dexcom |
| Operating Margin (TTM) | 18.37% | 21.95% | Stryker |
| EBITDA Margin (TTM) | 18.37% | 21.95% | Stryker |
| Return on Equity | 22.83% | 14.25% | Dexcom |
| Return on Assets (TTM) | 6.08% | 7.74% | Stryker |
| Free Cash Flow (TTM) | $630.70M | $3.49B | Stryker |
| Dividend Yield | N/A | 0.88% | N/A |
| 1-Year Return | 8.44% | 13.03% | Stryker |
| Price-to-Sales Ratio (TTM) | 7.31 | 6.06 | Stryker |
| Enterprise Value | $31.09B | $158.64B | Stryker |
| EV/Revenue Ratio | 7.23 | 6.66 | Stryker |
| Gross Profit Margin (TTM) | 59.53% | 63.78% | Stryker |
| Revenue per Share (TTM) | $11 | $62 | Stryker |
| Earnings per Share (Diluted) | $1.42 | $7.53 | Stryker |
| Beta (Stock Volatility) | 1.44 | 0.91 | Stryker |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Dexcom vs Stryker Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Dexcom | 1.24% | 2.65% | -4.52% | -5.51% | -10.58% | 3.12% |
| Stryker | 0.90% | 1.15% | -2.22% | -2.62% | -0.96% | 6.46% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Dexcom | 8.44% | -4.89% | -24.15% | 259.78% | 2,494.55% | 2,653.40% |
| Stryker | 13.03% | 75.08% | 102.30% | 284.33% | 733.68% | 616.53% |
Performance & Financial Health Analysis: Dexcom vs Stryker
| Metric | DXCM | SYK |
|---|---|---|
| Market Information | ||
| Market Cap | $31.44B | $144.40B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 5,083,030 | 1,358,260 |
| 90 Day Avg. Volume | 3,546,350 | 1,200,997 |
| Last Close | $80.95 | $381.91 |
| 52 Week Range | $57.52 - $93.25 | $329.16 - $406.19 |
| % from 52W High | -13.19% | -5.98% |
| All-Time High | $164.86 (Nov 15, 2021) | $406.19 (Jan 27, 2025) |
| % from All-Time High | -50.90% | -5.98% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.15% | 0.11% |
| Quarterly Earnings Growth | 0.25% | 0.07% |
| Financial Health | ||
| Profit Margin (TTM) | 0.13% | 0.12% |
| Operating Margin (TTM) | 0.18% | 0.22% |
| Return on Equity (TTM) | 0.23% | 0.14% |
| Debt to Equity (MRQ) | 100.24 | 80.83 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $6.56 | $55.43 |
| Cash per Share (MRQ) | $7.47 | $6.45 |
| Operating Cash Flow (TTM) | $987.70M | $4.77B |
| Levered Free Cash Flow (TTM) | $425.12M | $3.49B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.88% |
| Last 12-Month Dividend | N/A | $3.28 |
Valuation & Enterprise Metrics Analysis: Dexcom vs Stryker
| Metric | DXCM | SYK |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 56.46 | 50.16 |
| Forward P/E | 39.49 | 27.92 |
| PEG Ratio | 39.49 | 7.26 |
| Price to Sales (TTM) | 7.31 | 6.06 |
| Price to Book (MRQ) | 12.22 | 6.81 |
| Market Capitalization | ||
| Market Capitalization | $31.44B | $144.40B |
| Enterprise Value | $31.09B | $158.64B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.23 | 6.66 |
| Enterprise to EBITDA | 33.67 | 24.84 |
| Risk & Other Metrics | ||
| Beta | 1.44 | 0.91 |
| Book Value per Share (MRQ) | $6.56 | $55.43 |
Financial Statements Comparison: Dexcom vs Stryker
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | DXCM | SYK |
|---|---|---|
| Revenue/Sales | $1.04B | $6.02B |
| Cost of Goods Sold | $447.00M | $2.18B |
| Gross Profit | $589.00M | $3.84B |
| Research & Development | $145.20M | $407.00M |
| Operating Income (EBIT) | $133.70M | $1.17B |
| EBITDA | $219.00M | $1.52B |
| Pre-Tax Income | $154.30M | $1.02B |
| Income Tax | $48.90M | $132.00M |
| Net Income (Profit) | $105.40M | $884.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | DXCM | SYK |
|---|---|---|
| Cash & Equivalents | $904.90M | $2.32B |
| Total Current Assets | $4.55B | $13.02B |
| Total Current Liabilities | $3.04B | $7.93B |
| Long-Term Debt | $1.36B | $14.38B |
| Total Shareholders Equity | $2.27B | $20.93B |
| Retained Earnings | $1.70B | $18.86B |
| Property, Plant & Equipment | $59.10M | $1.67B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | DXCM | SYK |
|---|---|---|
| Operating Cash Flow | $167.90M | $719.00M |
| Capital Expenditures | $-87.00M | $-123.00M |
| Free Cash Flow | $96.80M | $127.00M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | DXCM | SYK |
|---|---|---|
| Shares Short | 8.49M | 4.91M |
| Short Ratio | 2.71 | 4.16 |
| Short % of Float | 0.03% | 0.01% |
| Average Daily Volume (10 Day) | 5,083,030 | 1,358,260 |
| Average Daily Volume (90 Day) | 3,546,350 | 1,200,997 |
| Shares Outstanding | 390.70M | 381.40M |
| Float Shares | 389.43M | 344.60M |
| % Held by Insiders | 0.00% | 0.05% |
| % Held by Institutions | 0.99% | 0.81% |
Dividend Analysis & Yield Comparison: Dexcom vs Stryker
| Metric | DXCM | SYK |
|---|---|---|
| Last 12-Month Dividend | N/A | $3.28 |
| Last 12-Month Dividend Yield | N/A | 0.88% |
| 3-Year Avg Annual Dividend | N/A | $3.09 |
| 3-Year Avg Dividend Yield | N/A | 0.27% |
| 3-Year Total Dividends | N/A | $9.26 |
| Ex-Dividend Date | N/A | Mar 31, 2025 |